Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study-Reference-Cited by-同舟云学术

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

Published:2016-10 Issue:10 Volume:17 Page:1409-1418
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

O'Brien Susan,Jones Jeffrey A,Coutre Steven E,Mato Anthony R,Hillmen Peter,Tam Constantine,Österborg Anders,Siddiqi Tanya,Thirman Michael J,Furman Richard R,Ilhan Osman,Keating Michael J,Call Timothy G,Brown Jennifer R,Stevens-Brogan Michelle,Li Yunfeng,Clow Fong,James Danelle F,Chu Alvina D,Hallek Michael,Stilgenbauer Stephan

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. p53 mutations in human cancers;Hollstein;Science,1991

2. Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go;Puiggros;Biomed Res Int,2014

3. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines;Hallek;Blood,2008

4. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia;Pospisilova;Leukemia,2012

5. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010

Cited by 298 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy;The Oncologist;2024-09-08

2. Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice;Blood Neoplasia;2024-09

3. Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments;Advances in Rheumatology;2024-08-21

4. Current Approaches and Novel New Agents in the Treatment of Chronic Lymphocytic Leukemia;JCO Oncology Practice;2024-06-07

5. Frequent response monitoring in chronic lymphocytic leukemia clinical trials: what is the value?;Blood Neoplasia;2024-06